Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with pemetrexed and platinum-based chemotherapy within its marketing authorisation for untreated unresectable advanced malignant pleural mesothelioma.
For information, the company have advised that the wording of the marketing authorisation for pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma is still to be determined and therefore they have requested a temporary suspension of this appraisal while this issue is resolved. NICE will continue to monitor any development and will update interested parties when the situation changes.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 4044
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Merck Sharpe and Dohme
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Mesothelioma UK
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- British Thoracic Society
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Aspire Pharma (pemetrexed) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb (ipilimumab, nivolumab) (confidentiality agreement signed, participating)
- Dr. Reddy’s Laboratories (UK) (pemetrexed) (confidentiality agreement not signed, not participating)
- Eli Lilly (pemetrexed) (confidentiality agreement not signed, not participating)
- Genus (pemetrexed) (confidentiality agreement not signed, not participating)
- Hospira (carboplatin, cisplatin) (confidentiality agreement not signed, not participating)
- Pfizer (pemetrexed) (confidentiality agreement not signed, not participating)
- Sandoz (cisplatin, pemetrexed) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (pemetrexed) (confidentiality agreement not signed, not participating)
- Sun Pharmaceuticals (pemetrexed) (confidentiality agreement not signed, not participating)
- Zentiva (pemetrexed) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 February 2025 | Suspended. For information, the company have advised that the wording of the marketing authorisation for pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma is still to be determined and therefore they have requested a temporary suspension of this appraisal while this issue is resolved. NICE will continue to monitor any development and will update interested parties when the situation changes. |
| 24 July 2024 | Following a request from the company, the timelines for this appraisal have been revised. The committee meeting will be held on 12 March 2025. |
| 12 June 2024 | Invitation to participate |
| 17 January 2024 - 14 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044 |
| 17 January 2024 - 14 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044 |
| 17 January 2024 | In progress. Scoping commencing |
For further information on our processes and methods, please see our CHTE processes and methods manual